Overexpressed galectin-3 in pancreatic cancer induces cell proliferation and invasion by binding Ras and activating Ras signaling.
Pancreatic cancer (PDAC) is a lethal disease with a five-year survival of 3-5%. Mutations in K-Ras are found in nearly all cases, but K-Ras mutations alone are not sufficient for the development of PDAC. Additional factors contribute to activation of Ras signaling and lead to tumor formation. Galect...
Main Authors: | Shumei Song, Baoan Ji, Vijaya Ramachandran, Huamin Wang, Margarete Hafley, Craig Logsdon, Robert S Bresalier |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2012-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3416861?pdf=render |
Similar Items
-
TOB1 suppresses proliferation in K‐Ras wild‐type pancreatic cancer
by: Yuru Bai, et al.
Published: (2020-02-01) -
The inhibition of pancreatic cancer progression by K-Ras-overexpressing mesenchymal stem cell-derived secretomes
by: Qingji Huo, et al.
Published: (2023-09-01) -
The energetics of nucleotide binding to RAS proteins
by: Worth, G, et al.
Published: (1992) -
Mutant K-Ras in Pancreatic Cancer: An Insight on the Role of Wild-Type N-Ras and K-Ras-Dependent Cell Cycle Regulation
by: Robert Ferguson, et al.
Published: (2023-03-01) -
The C-terminus of H-Ras as a target for the covalent binding of reactive compounds modulating Ras-dependent pathways.
by: Clara L Oeste, et al.
Published: (2011-01-01)